The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

CRISPR-Cas9 pioneer presented with National Medal of Technology and Innovation in White House awards ceremony.

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...